VCL::ROS1: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advanced Non-Small Cell Lung Carcinoma (NSCLC) with ROS1 gene rearrangements exhibits sensitivity to tyrosine kinase inhibitors (TKIs).
• Approximately 40 ROS1 fusion partners have been previously identified in NSCLC patients.
• Standard treatments include US Food and Drug Administration-approved TKIs.

Observation:

• A novel fusion partner involving the ROS1 gene was identified in an advanced NSCLC patient.
• This patient's tumor harbored the newly identified ROS1 fusion.

Findings:

• The patient with the novel ROS1 fusion demonstrated a significant and conclusive therapeutic response.
• The response was achieved using the current standard TKI treatment regimen.

Implications:

• This finding expands the spectrum of known ROS1 alterations in NSCLC.
• It suggests that patients with this novel fusion may benefit from existing ROS1-targeted therapies.
• Further research may validate this novel fusion as a target for NSCLC treatment.